Search Results

Article

Joanne Turner

Joanne Turner, PhD, is the chief scientific officer and the interim director of the Center for Microbe and Immunity Research at the Abigail Wexner Research Institute at Nationwide Children's Hospital. She is also an Elizabeth M. and Richard M. Ross Endowed Chair in Pediatric Research. Dr. Turner’s research focuses on immunity to mycobacterial infection in relation to aging.

Research Employee Access

The following links are ONLY for current employees:

Article

Davenport Lab

The Sleep Empowers Lab, led by Mattina Davenport, PhD, focuses on improving community sleep health through community-driven research and initiatives to improve sleep health equity by empowering populations.

Article

Center for Cancer Genomics at the National Cancer Institute (NCI CCG) Project Team

The BCR is a laboratory and biorepository within the Biopathology Center (BPC) that supports multiple cancer genomics projects for the Center for Cancer Genomics (CCG) at the National Cancer Institute (NCI) and other contracted entities.

Article

CHTN Pediatric Division

The Cooperative Human Tissue Network (CHTN) facilitates access to human tissue for research, accelerating scientific discoveries in medical diagnoses and treatment. The Pediatric Division is managed by the Biopathology Center at Nationwide Children’s Hospital.

Article

About Us

The BCR at Nationwide Children's Hospital is composed of six primary workgroups: Client Services Logistics Histology Pathology and Virtual Microscopy Molecular Informatics This subdivision of workgroups creates a modular system which allows the BCR flexibility and variety in the functions it

Article

News Archive

$13.1 Million Innovation Grant Expands Pediatric Health Care for Underserved Children The State of Ohio, Partners for Kids, Nationwide Children’s Hospital and Akron Children’s Hospital unite to expand innovative model of health care delivery for underserved children (June 18, 2012).

Article

ALCHEMIST

The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST, is a group of clinical trials for patients with certain types of early-stage non-small cell lung cancers (NSCLC) that have been treated surgically.

Article

Exceptional Responders

The National Cancer Institute (NCI) has embarked on the Exceptional Responders (ER) Initiative to understand the molecular underpinnings of exceptional responses to treatment, primarily via chemotherapy, in cancer patients.